East Asia Pharmaceutical released its 2026 interim report, with total operating revenue of 466 million yuan and net profit attributable to the parent company of minus 118 million yuan, a decrease of 88.1487 million yuan compared with the same period last year, widening the loss. Net cash inflow from operating activities was 51.814 million yuan, the asset-liability ratio was 44.48 percent, and the gross margin was 23.88 percent, down 6.27 percentage points year on year. Return on equity was minus 6.95 percent, down 5.32 percentage points year on year. Diluted earnings per share were minus 1.03 yuan, a decrease of 0.77 yuan year on year. The number of shareholders was 10,400, and the top ten shareholders held 56.90 percent of the total share capital.
Zhejiang East Asia Pharmaceutical Co. Ltd.Company reported a widened net loss of 118 million yuan for 2026 interim.
